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Abstract. The ability to predict subcutaneous (SC) absorption rate and tissue distribution of therapeutic
proteins (TPs) using a bottom-up approach is highly desirable early in the drug development process
prior to clinical data being available. A whole-body physiologically based pharmacokinetic (PBPK)
model, requiring only a few drug parameters, to predict plasma and interstitial ﬂuid concentrations of TPs
in humans after intravenous and subcutaneous dosing has been developed. Movement of TPs between
vascular and interstitial spaces was described by considering both convection and diffusion processes
using a 2-pore framework. The model was optimised using a variety of literature sources, such as tissue
lymph/plasma concentration ratios in humans and animals, information on the percentage of dose
absorbed following SC dosing via lymph in animals and data showing loss of radiolabelled IgG from the
SC dosing site in humans. The resultant model was used to predict tmax and plasma concentration proﬁles
for 12 TPs (molecular weight 8–150 kDa) following SC dosing. The predicted plasma concentration
proﬁles were generally comparable to observed data. tmax was predicted within 3-fold of reported values,
with one third of the predictions within 0.8–1.25-fold. There was no systematic bias in simulated Cmax
values, although a general trend for underprediction of tmax was observed. No clear trend between
prediction accuracy of tmax and TP isoelectric point or molecular size was apparent. The mechanistic
whole-body PBPK model described here can be applied to predict absorption rate of TPs into blood and
movement into target tissues following SC dosing.
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INTRODUCTION
Therapeutic proteins (TPs) have been used clinically for
many years (e.g. insulin, erythropoietin (EPO), growth
hormone), and with the more recent development of mono-
clonal antibodies (mAbs), fusion proteins, antibody-drug
conjugates, etc. represent a fast-growing sector of pharma-
ceutical development (1,2). Subcutaneous (SC) dosing is a
common administration route for TPs, which cannot usually
be given orally due to their poor bioavailability (3,4).
SC dosing delivers drugs into the interstitial space of the
hypodermis, located between the skin and the muscle. The
thickness and structure of the hypodermis varies between
species and also with body location (5). The interstitial space
is the area between the capillary endothelial cells and the
tissue cells themselves (6). There have been several reviews
of the structure of the interstitial space and the transport of
proteins from the interstitium into the blood and lymph (5–9);
therefore, only brief details will be given here. The intersti-
tium is ﬁlled with extracellular matrix, comprised mainly of
collagen, elastin and glycosaminoglycans. Together these
elements give the interstitial ﬂuid a gel-like consistency and
a net negative charge, which inﬂuences drug distribution and
transport at the administration site (5). From the interstitial
space, drugs can gain access to the systemic circulation by
either direct diffusion/transport across the endothelial cells
into capillaries or by movement with the convective ﬂow of
interstitial ﬂuid into the lymphatic vessels, which eventually
drain into the blood.
Due to their size and polarity, TPs have limited direct
diffusion across endothelial cell membranes and movement to
the blood occurs mainly via diffusion and convection through
pores in the endothelial wall, which is limited by protein size
(6,7,10). For large TPs, a substantial portion of absorption into
the systemic circulation following SC administration occurs via
the lymphatic system (11–14). Supersaxo et al. (13) showed a
positive correlation between increasing protein size and the
contribution of lymphatic absorption following SC dosing in
sheep (11–14). As lymph ﬂow is much slower than blood ﬂow
from the tissues (7), absorption via the lymphatics is likely to
contribute to the late maximum concentration (Cmax) observed
following SC administration of many TPs (7,12,14).
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Several pharmacokinetic (PK) models have been con-
structed to describe/predict the rate and extent of SC
absorption of TPs; these have been reviewed recently (15).
The vast majority of these models are empirical in nature and
require ﬁtting of clinical data to parameterise the models,
hindering the prediction of SC absorption in early drug
development when such data are unavailable. In addition, the
accuracy of the prediction of SC absorption and bioavailabil-
ity using allometry of animal data is inadequate (5). Ibrahim
et al. (11) presented a PK model for dermal clearance, where
lymph and blood absorption of free and protein-bound
solutes was described based on the 2-pore hypothesis. The
model predicted blood capillary permeability and percentage
of dose absorbed through the lymph for a variety of solutes
with good accuracy and precision relative to the observed
clinical data (11). However, this model was not linked to a PK
model describing drug disposition in the rest of the body.
Therefore, the model predictions for absorption could not be
compared to clinical data for Cmax and time of Cmax (tmax). In
addition, the dermal clearance model could not account for
the return of drug to the interstitial ﬂuid at the SC site via
recirculation which is known to be an important factor in
interpretation of experimental data (15). A whole-body
physiologically based PK (PBPK) model incorporating the
SC dosing site as part of the skin was reported recently (16).
This model accounted for the recirculation of TP to the SC
site and allowed prediction of Cmax and tmax. However, the
movement of protein was based solely on lymphatic transport
and hence the model may not be suitable for smaller TPs
where direct absorption of drug into blood at the SC site may
be an important absorption route (13).
In the current study, a whole-body PBPK model has
been developed to mechanistically predict the rate of SC
absorption and plasma and interstitial ﬂuid concentrations
of TPs in humans. The model requires a limited number of
drug parameters which makes it suitable even at the early
stage of drug development. The model predicts the TP
absorption rate and tissue distribution based upon the
molecular size of the protein using a 2-pore framework
(10,17,18). A limitation of the model is that at the moment,
bioavailability cannot be predicted mechanistically from
in vitro data, so an empirical estimate of bioavailability is
needed. The prediction accuracy of tissue distribution at
steady state, plasma concentration proﬁles and tmax follow-
ing SC dosing of TPs, including both small TPs and mAbs,
using the PBPK model is presented.
MATERIALS AND METHODS
Structure of the PBPK Model
A human whole-body PBPK model was developed and
implemented in the Simcyp Simulator (V14 R1, Simcyp,
Shefﬁeld, UK). The model contains 11 tissues, each being
described by two compartments, representing vascular and
interstitial spaces (Fig. 1). This tissue structure was also used
to represent the SC dosing site. In addition to the ﬂow of
blood to and from each organ, the ﬂow of lymph from
individual tissues is accounted for. The lymph ﬂow from each
tissue in the PBPK model is collected into a single compart-
ment (central lymph), and from here, the total lymph ﬂow is
returned to the venous circulation, maintaining ﬂuid balance
(Fig. 1). The differential equations used to describe the
movement of TP in the PBPK model are shown below (Eqs. 1
to 5).












where the subscript org indicates the organ (adipose, bone,
brain, gut, heart, lung, muscle, pancreas, skin, spleen and
SC site) and Vvorg, Cv,org, Qorg, Cab, Lorg, σav,org, PSs,org,
PSl,org, Pes,org, Pel,org and Ci,org are the vascular space
volume, vascular space concentration, blood ﬂow, concen-
tration in arterial blood, lymph ﬂow, average vascular
reﬂection coefﬁcient, permeability surface area product
(PS) through small pores, PS through large pores, small
pore peclet number, large pore peclet number and inter-
stitial ﬂuid concentration, respectively. For the lung, Qorg
represents the entire cardiac output. σav,org takes into
account the fractional total hydraulic conductance
accounted for by small and large pores and the osmotic
reﬂection coefﬁcient for small and large pores in a given
organ (10).
V i;org  dCi;orgdt ¼ Lorg  1−σav;org
  Cv;org






− Lorg  1−σL;org
  Ci; org ð2Þ
where Vi,org and σL,org are the interstitial space volume and
lymph reﬂection coefﬁcient, respectively.






− Ltotal  CLN
ð3Þ
where VLN, CLN and Ltotal are the central lymph
compartment volume, the central lymph compartment
concentration and total lymph ﬂow (the sum of Lorg for
all tissues), respectively. The summation here is for all
tissues.







−QC  Cvb þ Ltotal  CLN
ð4Þ
where Vvb, Cvb and Qc are the venous blood volume,
concentration in venous blood and cardiac output, respec-
tively. The summation here is for all tissues except lung,
spleen, gut and pancreas.
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Vab  dCabdt ¼ Qc−Llung
  Cv;lung− Qc−Llung
  Cab− CLpBP  Cab
ð5Þ
where Vab, Llung, Cv,lung, BP and CLp are the arterial blood
volume, lung lymph ﬂow, lung vascular space concentration,
blood/plasma concentration ratio and plasma clearance,
respectively. Here, ﬂow balance has been imposed, i.e. the
ﬂow into the arterial blood equals to the ﬂow out of this
compartment.
Some alterations to Eq. 1 were required for the liver
vascular space, as detailed in Eq. 6.
Vvliver  dCv;liverdt ¼ Qliver  Cabð Þ þ Qgut−Lgut
 
 Cv;gut þ Qspleen−Lspleen
 











 Cv;liver− Lliver  1−σav;liver
  Cv;liver






where Vvliver, Cv,liver, Qliver, Qgut, Lgut, Cv,gut, Qspleen, Lspleen,
Cv,spleen, Qpancreas, Lpancreas, Cv,pancreas, Lliver, σav,liver, PSs,liver,
Pes,liver, PSl,liver, Pel,liver and Ci,liver, are the liver vascular
space volume, liver vascular space concentration, hepatic
artery blood ﬂow, gut blood ﬂow, gut lymph ﬂow, gut vascular
space concentration, spleen blood ﬂow, spleen lymph ﬂow,
spleen vascular space concentration, pancreas blood ﬂow,
pancreas lymph ﬂow, pancreas vascular space concentration,
liver lymph ﬂow, liver average vascular reﬂection coefﬁcient,
liver PS through small pores, liver small pore peclet number,
liver PS through large pores, liver large pore peclet number
and liver interstitial ﬂuid concentration, respectively. Qliver
represents 19% of cardiac output (19).
SC dose was described as a bolus input to the
interstitial compartment of the SC dosing site. The initial
concentration for the SC interstitial space is deﬁned as
(dose×F)/Vint,SC site, where F is the bioavailability. For all
the other compartments in the PBPK model, the initial
concentration is 0.
System Parameters
System parameters were taken from a population
representative Sim-Healthy Volunteer simulation in the
Simcyp Simulator V14R1. Values for whole organ volume,
fraction of vascular space, fraction of extracellular water and
blood ﬂow to each tissue are given in Table I; these
parameters are the same as those used for modelling of small
molecule drugs in Simcyp (20,21). The body weight and
cardiac output were 80.7 kg and 356 L/h, respectively. The
remaining blood ﬂow, lymph ﬂow and body volume were
assigned to a ‘bypass’ compartment to ensure mass balance.
The interstitial space, venous blood and arterial blood
volumes are calculated from Eqs. 7 to 9.
V i;org ¼ total organ volume  FEWð Þ – Vvorg ð7Þ
Fig. 1. Structure of the permeability limited tissue model incorporated into the whole-body PBPK model for therapeutic proteins. Solid red and
blue lines represent arterial and venous blood ﬂow; dashed black lines represent lymph ﬂow. LN, L, Q, PS and σ represent central lymph,
lymph ﬂow, blood ﬂow, permeability surface area product and reﬂection coefﬁcient, respectively
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where FEW is the fraction of extracellular water in the tissue.
















Lymph ﬂow to each tissue and total lymph ﬂow data for
humans were collated from the literature where possible. Due
to reabsorption of ﬂuid in the lymph nodes, the lymph ﬂow
measured in the thoracic duct or other sites that are distal to
the lymph nodes may give a lower value of ﬂuid ﬂow than
that which drains from the interstitial spaces of the tissues (6).
In the PBPK model, it was assumed that lymph node ﬂuid
reabsorption is negligible, and therefore, the estimate of total
lymph ﬂow (0.00386 L/h/kg) reﬂects the summation of the
ﬂow of ﬂuid from the blood into the interstitial space of all of
the tissues combined. The percentage of total lymph ﬂow
returning from each individual tissue is detailed in Table I.
Estimates were based on data collated from the literature for
humans or allometrically scaled from animals. Where a range
of values were found, a weighted mean value was chosen. The
spleen and bone do not have lymph vessels exiting the tissue,
and so lymph ﬂow was set to 0 L/h (6,22–25).
The time course of protein in spleen and bonewasmodelled
using parameters that ensure rapid equilibration between the
vascular and interstitial spaces (PSs,org and PSl,org = 0.1, and
Pes,org/e
Pes,org−1 and Pel,org/ePel,org−1 = 1) and hence operate
similar to well stirred compartments.
Movement of TPs between the vascular and interstitial
spaces is described mechanistically by considering convection
and diffusion processes using a 2-pore model (6,10). This
model assumes that the endothelial membrane contains pores
allowing the ﬂow of ﬂuid and proteins between the vascular
and interstitial spaces. The pores in the endothelial mem-
brane are considered to be of two discrete sizes; large and
small pores. For each tissue, the pore sizes and the relative
frequency of the large and small pores were deﬁned by
collation of data from the literature where available and
manual optimisation when the values were not available
(see the Model Validation section). Optimisation was per-
formed by ﬁxing the tissue volumes and blood and lymph
ﬂows and manually adjusting the pore sizes and relative
frequency of the large and small pores by trial and error until
the predicted concentration ratio of protein in plasma, and
the lymph was comparable to observed data. The pore radii
and the ratio of small pores to large pores in each tissue are
given in Table I.
Drug-Specific Parameters
The assumptions and derivation of the 2-pore model
have been detailed extensively in previous publications, and
interested readers are referred to the following references
(6,10). Brieﬂy, this model describes the convection and
diffusion of proteins through the pores in the endothelial
membrane based on the radius of the pore relative to the
hydrodynamic radius (Rs) of the TP. If the TP is large
compared to the pore (Rs>radius of the pore), then there will
be no movement of the TP through that particular set of
pores. The methods used to calculate values of σav, PSs, PSl,
Pes and Pel in each of the tissues are detailed in references
(6,10). The Rs of each TP was calculated from molecular
weight using Simcyp V14 R1. The movement of TP from
interstitial space into lymph is not considered to be restrictive
and therefore σL is set to 0 for all tissues and TPs. Binding is
not considered within the lymphatics of the PBPK model.



















Adipose 22.7 0.031 0.141 5.00 12.8 7.0b 20a 500a
Bone 3.95 0.05 0.098 5.00 0.00 9.0a 33b 46a
Brain 1.34 0.05 0.092 12.0 1.05 0.6b 18 20,000,000b
Gut 1.22 0.05 0.267 15.0 12.0 4.8 25b 500a
Heart 0.359 0.042 0.313 4.00 1.00 4.8 25 400b
Kidney 0.325 0.07 0.283 19.0 8.50 7.4 20 200b
Liver 1.61 0.05 0.165 25.5 33.0 9.0 33 46
Lung 0.547 0.185 0.348 100 3.00 9.0b 25b 45b
Muscle 31.3 0.027 0.091 17.0 16.0 4.5 22 2000b
Pancreas 0.123 0.05 0.12 0.0100 0.30 6.0a 20a 3610a
Skin 3.15 0.05 0.623 5.00 7.30 6.0a 20a 500a
Spleen 0.150 0.05 0.208 0.0200 0.00 9.0a 33a 46a




System parameters based on the Population Representative Sim-Healthy Volunteer in the Simcyp Simulator V14R1. Whole organ volume,
fraction of vascular space, fraction of extracellular water and blood ﬂow to each tissue (20,21); full references for lymph ﬂow, pore sizes and
large pore/small pore values (prior to optimisation) can be found in the Supplemental Material
aNo observed data available, values optimised to recover observed lymph/plasma concentration data
bObserved values optimised to recover observed lymph/plasma concentration data
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Model Validation
Full PBPK Model
Plasma (Cp) and tissue Ci concentrations at steady state
were simulated for theoretical TPs covering a range of Rs
(1–11 nm). CLp was set to zero to ensure steady-state
concentrations were achieved in all compartments of the
PBPK model during the simulations. The simulated Ci/Cp
ratios were compared with literature values of lymph/plasma
concentration ratios from a variety of proteins for tissues in
humans and experimental animals, with the assumption that
lymph concentrations exiting tissues are a measurable
surrogate of Ci at steady state (26) (references for the
collated literature values are given in the Supplemental
Material).
Development of the SC Site Model
Physiological parameters for a 5 mL volume were used to
model the SC dosing site. The interstitial volume for the dosing
site in the model was 3 mL, estimated using data for the
diameter of the SC depot of radiolabelled IgGor albumin in skin
with the assumption that the dose is conﬁned to the interstitial
ﬂuid immediately following injection (Table II) (27–30).
Observed data for the rate of radiolabelled IgG (28–30)
loss from the SC dosing site were used to determine the
lymph ﬂow needed for the SC site. The lymph ﬂow exiting the
SC site was calculated under the assumption that IgG is too
large to diffuse through endothelial pores; hence, all loss from
the SC site is via lymph drainage, and there is no restriction to
IgG entering the lymphatic system. Transcytosis of IgG via
binding to the neonatal Fc receptor (FcRn) in the endothelial
cells was not considered as it provides a minimal route of
absorption (14,31), see Discussion section for more details.
Lymph ﬂow was calculated for each individual study using
Eq. 10 (28–30) and the reported rate (K) and SC depot
volume data calculated previously (Table II). The average
fractional rate of loss for IgG was 0.0009725 min−1, providing
an average SC site lymph ﬂow of 0.00225 mL/min.
K for IgG loss from SC site ¼ SC site lymph flow
Volume of SC depot
ð10Þ
Cp and Ci concentrations at steady state were simulated
for theoretical TPs with Rs of 1–11 nm and compared with
literature values of lymph/plasma ratios for the SC site in
humans and experimental animals to ensure that use of the
pore radii and ratio of small/large pores for the skin were also
suitable for the SC site. CLp was set to 0 for the theoretical
TPs. The model was optimised using percentage of dose
absorbed in the lymph data reported for sheep (13).
Unfortunately, such data from humans are lacking in the
literature. Data from sheep were considered to give a more
representative description of the percentage of dose absorbed
in the lymph than data reported for scruff species such as rats
and mice. This is because the structure of the SC tissue is
markedly different in scruff species compared to higher
mammals (5). Final model parameters are shown in Table I.
Model Application
The model was then used to predict tmax and plasma
concentration proﬁles for 12 TPs (MW 8–150 kDa) following
SC dosing. The input parameters for each simulation are
given in Table I of the Supplemental Material. Observed
bioavailability and intravenous clearance values for each TP
were collated from the literature. Where intravenous clear-
ance data were unavailable, the values were determined using
the parameter estimation facility in the Simcyp Simulator.
The simulation results were compared with observed data
from the literature. The observed concentration data were
digitised using GetData graph digitiser version 2.22 (GetData
Graph Digitizer, 2012, http://getdata-graph-digitizer.com/).
Prediction accuracy for tmax was assessed using a measure of
fold error. In addition, simulated Cmax values were compared
to observed values using the same method. Correlations
between prediction accuracy of Cmax or tmax and TP size were
assessed. In addition, the relationship between prediction
accuracy of Cmax or tmax and TP isoelectric point (pI) was
investigated.
Sensitivity Analysis
Manual sensitivity analysis was performed to assess the
impact of lymph ﬂow on the tmax in the interstitial space and
the steady-state Ci/Cp ratios. Hypothetical proteins with Rs
of 1–7 nm were simulated with CLp set to 0 L/h and with the
dose administered as a bolus into the venous blood compart-
ment. The total lymph ﬂow was varied between 0.1- and 10-
fold of the standard value.

















Albumin 15 2.2 1.1 5.58b NR NR Arm (27)
IgG 8 1.41 0.71 1.47 0.157 0.00230 Hand (28)
IgG 14 1.70 0.85 2.57 0.093 0.00239 Forearm (29)
IgG 10 1.60 0.80 2.14 0.095 0.00204 Hand (29)
Weighted mean values 3.25 0.110 0.00226
NR not reported, K drainage rate constant of IgG injected into SC tissue
aVolume calculated assuming IgG dose distributes into a spherical volume
bCalculated from a diffusion area of 3.8 cm2 , assuming the area was for a circle
160 Gill et al.
RESULTS
Model Validation
Predicted and observed Ci/Cp ratios for each tissue are
shown in Fig. 2; the bone, pancreas and spleen are not
presented due to a lack of observed data in the literature. No
obvious or systematic differences in observed Ci/Cp ratios
were noted when data in experimental animals and humans
(where available) were compared, so the entire experimental
data set is presented. The predicted Ci/Cp ratios were similar
to the observed data, showing that the model predicted
protein distribution into the interstitial space well. For
example, for a TP with radius of 3.55 nm (equivalent to
albumin), the predicted Ci/Cp ratio was 0.87 for the liver,
compared to Ci/Cp ratios of 0.78–1.00 reported in vivo (26).
Development of the SC Site Model
Observed data for the percentage of radiolabelled IgG
dose remaining at the SC injection site over time (28–30)
were plotted against the simulated data for a TP with
hydrodynamic radius of 5 nm (Fig. 3a). The predicted Ci/Cp
ratios for the SC site were comparable to the observed values
collated from the literature (26,32–34), as shown in Fig. 3b.
Therefore, the pore radii and ratio of small/large pores for the
skin were suitable for the SC site. The predicted percentage
of dose absorbed through the lymph for proteins with a range
of sizes compared to values from sheep (13) are shown in
Fig. 3c.
Model Application
The dataset of observed concentration proﬁles following
SC dosing contained 54 studies/dose levels, with up to 14 sets
of observed data per TP. Simulated plasma concentration
proﬁles following SC dosing for the included TPs were
generally similar to observed data (Fig. 4, linear plots are
shown in Supplemental Material Fig. 1). The prediction
accuracy of Cmax and tmax for the complete dataset and
summary statistics are presented in Table III. Simulated Cmax
was within 3.1-fold of observed values, with approximately
half (46%) of the simulated Cmax values falling within 0.8–
1.25-fold of the observed values. A third (31%) of tmax
predictions were within 0.8–1.25-fold of observed values, with
all predictions falling within 3.3-fold. There was no systematic
bias for over or underprediction of Cmax, although a general
trend for underprediction of tmax was apparent (Fig. 5). The
extent of the tmax underprediction did not correlate with the
molecular size of the TP (Fig. 5b). For TPs with molecular
Fig. 2. Predicted and observed Ci/Cp ratios for proteins with a range of hydrodynamic radii. a Adipose, b brain, c gut, d heart, e kidney, f liver,
g lung, h muscle and i skin. Blue diamonds indicate observed data [References in Supplemental Material]; Red line denotes predicted data
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sizes <150 kDa, tmax was generally predicted within 0.30- and
2.9-fold of observed values, similarly for mAbs (molecular
weight ~150 kDa), the tmax was predicted within 0.44- and 1.2-
fold of observed values (Fig. 5b). In addition, no clear trend
between prediction accuracy of Cmax or tmax and TP pI was
apparent (Fig. 5c, d).
DISCUSSION
In the current study, a whole-body PBPK model has been
developed to describe the tissue distribution and SC absorption
rate of TPs. Movement of TPs within the model is based on the
2-pore hypothesis (10), with hydrodynamic radius being the only
drug-speciﬁc parameter used to predict the rate of absorption
and the extent of tissue distribution. Use of the 2-pore model
will have minimal impact for the prediction of mAb distribution
compared to previously published models where distribution is
described by convection alone. For smaller TPs, where diffusion
through endothelial pores may have a larger contribution to
distribution, this model potentially offers an advantage over
PBPK models considering only convective movement. In
addition to the usual physiological data required for PBPK
models (organ weights, blood ﬂows etc.), lymph ﬂow and pore
sizes in each tissue were needed to describe the disposition of
TPs. Obtaining accurate estimates of lymph ﬂow from different
organs in humans is challenging as the clinical measurement of
lymph ﬂow is an invasive procedure and as such is not usually
conducted in healthy individuals. Obtaining reliable estimates of
lymphatic ﬂow is also difﬁcult because lymph cannulation may
lead to changes in ﬂow, making it difﬁcult to get an estimate of
the unperturbed lymph ﬂow (62). In the model developed here,
we used physiological estimates of lymph ﬂow for the different
tissues. Unsurprisingly, when used in the context of the PBPK
model, these lymph ﬂow values in addition to the optimised pore
sizes were suitable to accurately capture the steady-state tissue
lymph/plasma concentration ratios of TPs with a large size range
(Fig. 2). Sensitivity analysis showed that the steady-state lymph/
plasma concentration ratios were not sensitive to individual
tissue lymph ﬂows, whereas interstitial ﬂuid tmax was
(Supplemental Material Figures 2–3). Although most of the
observed lymph/plasma concentration ratio data are taken from
animals for those proteins where human data are also available,
large interspecies differences are not evident, indicating that the
animal data may be suitable to use for model development and
validation where human data are lacking.
The SC site part of the model was also developed using
experimental data to determine suitable physiological values
for the lymph ﬂow, interstitial volume and endothelial pore
radii. The resulting model could reasonably predict the
systemic tmax for a wide range of TPs, with one third of the
predicted values falling within 0.8–1.25-fold of observed
values. Half the simulated Cmax values were within 0.8–1.25-
fold of observed values. The reasonable prediction of Cmax is
unsurprising as it is not only dependent on the absorption
rate but also on bioavailability, which was used as an input
parameter to the model. A previous dermal clearance model,
also based on the 2-pore hypothesis, used similar values for
the radii of small and large pores; 5 and 25 nm, respectively
(11), compared to the values used here (5 and 20 nm). The
lymph rate values used in the two models were also similar
(8 and 18×10−6/s). Previously published models describing SC
absorption of proteins incorporating both lymph and blood
absorption rates have generally not accounted for the
redistribution of TP from the systemic circulation (35,36)
but instead have modelled the SC compartment as an
absorption site only. However, extra-vascular distribution of
TPs is known to be important; for instance; absorbed
trastuzumab molecules have been estimated to circulate
through the lymphatic system four to ﬁve times on average
prior to elimination (63). A recent model accounting for
redistribution of TP into the SC site interstitial ﬂuid did not
incorporate direct blood absorption (16). An advantage of the
current model is that it accounts for potential subsequent
redistribution of TP into the interstitial ﬂuid at the SC site
following absorption and circulation in the blood, which is a
closer representation of the processes that occur in vivo. In
addition, the model developed here considers direct blood
absorption at the SC site, which may be important for smaller
TPs (13), and hence should give a more realistic description
of SC absorption rate.
Fig. 3. a Predicted and observed percentage of radiolabelled IgG
dose remaining at the dosing site following bolus SC dosing; Red line
denotes predicted data; Blue diamonds indicate observed data
(28–30). b Predicted and observed Ci/Cp ratios for the SC site; Red
line denotes predicted data; Blue diamonds indicate observed data
(26,32–34). c Predicted and observed percentage of dose absorbed
through the lymph for proteins of varying sizes;Red line denotes predicted
data; Blue diamonds indicate observed data from sheep (13,35,36)
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The diffusion rate through the interstitial space is dictated by
molecular size and physical and electrostatic interaction with the
various components of the interstitium (e.g. collagen and glycos-
aminoglycans) (7,12,64). Decreased distribution at the SC injection
site and increased electrostatic interactions are expected for TPs
with a positive charge at neutral pH (5,35,65). Several studies have
shown delayed SC absorption of positively charged compounds
compared to negatively charged molecules of the same molecular
size (65,66) and reduced SC bioavailability of mAbs with higher pI
values (67). Prediction accuracy of TPCmax and tmax was compared
with pI for the current dataset; however, no correlation was
apparent between the accuracy of predictions and the pI of the TPs
(Fig. 5). Unfortunately, the majority of TPs used covered a limited
range of pI (5.2 to 8.8), with the exception of IL-11 (pI=11.2).
Therefore, it cannot be conﬁrmed from this analysis if charge has
an important inﬂuence onTP distribution and absorption rate from
the SC site; however, it does not appear to be the main/only cause
of the poor prediction of tmax for certain TPs. Similarly, Mach et al.
(68) suggested that electrostatic interactions are unlikely to have a
major inﬂuence on mAb absorption rate and bioavailability unless
they have a signiﬁcantly positive charge and are administered at
low concentrations. In addition, ex vivo studies have shown that
Fig. 4. Predicted and observed plasma concentrations for TPs following SC dosing.
a IGF-1; b, c IL-2; d Anakinra; e, f IL-10; g IL-11; h, i hGH; j, k EPO; l Albumin;
m Tralokinumab; n Etanercept; o Omalizumab. Symbols represent observed data; lines
represent predicted data. a: blue, open diamond, green, purple and red symbols/lines=40,
40, 50, 80 and 100 μg/kg doses (37–39); b: black and purple symbols/lines=0.03 and
0.06 mg/m2 doses (40); c: blue, green and red symbols/lines=3, 3.75 and 4.5 mg doses (41);
d: blue symbols/line=100 mg dose (42); e: olive green, purple, grey, blue and green
symbols/lines=1, 2.5, 5, 8 and 10 μg/kg doses (43,45); f: red, green and black symbols/
lines=1.75 mg, 25 and 50 μg/kg doses (44,45); g: green, blue, red and purple symbols/
lines=3, 10, 25 and 50 μg/kg doses (46); h: blue, green and red symbols/lines=600, 1200
and 1800 mIU doses (47); i: red and blue symbols/lines=1.3 mg/m2 and 0.033 mg/kg doses
(48,49); j: purple, black, red, grey, blue, green and open diamond symbols/lines=0.188,
0.313, 0.375, 0.625, 0.938, 1.88 and 1.88 μg/kg doses (50–53); k: green, red, grey, blue,
purple, orange and black symbols/lines=2.81, 3.75, 5.63, 7.50, 8.44, 11.3 and 15 μg/kg
doses (50); l: blue symbols/line=100% of dose (27); m: green and red symbols/lines=150
and 300 mg doses (54); n: red, green and blue symbols/lines=10, 25 and 50 mg doses (55–
58); o: green and blue symbols/lines=150 and 300 mg doses (59)
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interactions with other charged formulation excipients can prevent
marked electrostatic interaction between the TP and the SC tissue
(68). For in-depth discussion of the impact of TP chemistry and
formulation impacts on SC absorption, please see Kinunnen et al.
(65).
The site and depth of SC injection can also inﬂuence
the local distribution and hence absorption of TPs (12,69–
72). The extent of absorption is generally similar between
dosing sites, but the rate of absorption may vary (5). For
example, following SC administration of 1 mg/kg rituxi-
mab to the foot or back of rats, tmax was 12 h and
4.6 days, respectively, whereas bioavailability was ~70%
for both administration sites (72). In contrast, no marked
differences in the exposure and bioavailability of
golimumab were apparent following SC administration in
the upper thigh, arm or abdomen of healthy adults (73).
Regional differences in blood and/or lymph ﬂow are
thought to contribute to this site-speciﬁc variation in
absorption rate (12,71). In addition, exercise, heating and
rubbing increase local lymph ﬂow rate (5,74,75) and hence
may affect distribution rate, tmax and bioavailability. Other
factors can also inﬂuence SC absorption and bioavailabil-
ity of TPs, including those related to the formulation
(pH, viscosity, osmolality, aggregation, excipients), admin-
istration (dose level, volume) and patient (disease)
(5,12,50,65,68,72,73). Unfortunately, information relating
to formulations, dose site and volumes and patient
temperature/movement were generally unavailable for the
studies used to supply the observed data herein.
Therefore the impact of these factors on prediction of
SC absorption rate using the PBPK model could not be
investigated.
In this study, a PBPK model was developed to
incorporate physiological data and aid mechanistic under-
standing and prediction of the rate of SC absorption.
However, a general trend for underprediction of tmax was
observed when using the PBPK model. Lag times of up to
3 h have been included in other models of TP SC
absorption to describe the time delay between dose and
recovery in central lymph (14,36,45,76–78). Similarly, the
radiolabelled IgG data used for model development
showed a lag of ~0.5 h between dosing and loss of IgG
from the dose site (28–30). In contrast, the required lag
time for pegylated EPO was found to be negligible for all
species apart from rat in a population PK model (79).
Unlike previous models (14,36,45,69,72,80–82), a lag time/
delay compartment is not included in the PBPK model. It
is currently unknown whether the lymphatic transport or
movement through the interstitial ﬂuid at the SC site is the
rate-limiting step in SC absorption (5). Multiple factors can
contribute to the observed delay, as described above, and a
mechanistic description incorporating all these processes is
not available. However, as the observed, tmax for most TPs
is >4 h, and for proteins larger than albumin, tmax is >50 h,
incorporating an empirical lag time of ~1 h to account for
the transfer of TP from injection site to interstitial space/
lymphatics would have minimal impact on the prediction
accuracy of tmax.
Fig. 5. Prediction accuracy of Cmax (a, c) and tmax (b, d) compared to hydrodynamic radius (a, b) or isoelectric point (c, d). Blue diamonds
denote prediction accuracy for individual studies/dose levels; Red line represents mean prediction accuracy for each TP; Black line indicates line
of unity; . . . 0.8 to 1.25-fold prediction accuracy; - - - 2-fold prediction accuracy
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Transcytosis of mAbs across endothelial cells via binding to
FcRn may allow direct access to blood at the SC site. However,
evidence for the importance of this process to the rate of SC
absorption is contradictory. SC dosing of mAbs in FcRn
knockout mice showed SC bioavailability was 3-fold lower than
in that wild-type mice (31). Correspondingly, increasing FcRn
afﬁnity at pH 6 improved bioavailability in mice (83). In
contrast, data from cynomolgus monkeys showed no improve-
ment in mAb bioavailability and a decrease in absorption rate
when FcRn binding at pH 6 was increased while maintaining no
direct binding to FcRn at pH 7.4 (84). Similarly, modelling
efforts to describe SC absorption of mAbs incorporating the
FcRn contribution have given conﬂicting results. Predicted
absorption via FcRn-mediated trancytosis when using such
models suggests this route provides <91% (85), 32% (63) or
~0% (14) of the overall systemic absorption in rats, mice and
humans, respectively. In addition, lymph ﬂow rate was shown to
be the only inﬂuential factor for predicted tmax (14). Although
FcRn may have a role in the protection of mAbs from
catabolism at the SC site, and hence bioavailability, it is
uncertain whether FcRn-mediated transcytosis is an important
route of mAb absorption (31,83). Using the PBPK model
herein, no clear correlation was observed between TP type
and the accuracy of tmax predictions. This indicates that the
model is suitable for both smaller TPs and mAbs and suggests it
is not necessary to include the FcRn recycling mechanism in the
current model, although this would need to be considered if
efforts were made to mechanistically predict bioavailability of
mAbs.
One limitation of the current model is the inability to
mechanistically predict bioavailability and hence the require-
ment for a measured value. Bioavailability is highly variable
between subjects and species, with no correlation to molec-
ular size (5,86). For mAbs, which all have a similar molecular
size, bioavailability usually ranges from 50 to 100% (31).
Incomplete absorption is due to degradation and/or catabo-
lism at the SC site and potentially within the lymphatic system
prior to the TP entering the systemic circulation. No
difference in the fraction of EPO dose recovered in
peripheral and central lymph was reported in cannulated
sheep, suggesting no loss of EPO during lymph transit from
the dosing site to the central blood stream (36) However, the
opposite was found for human growth hormone (87). In
addition to pre-systemic nonspeciﬁc clearance, target-
mediated drug disposition (TMDD) may contribute to
incomplete bioavailability (88) of TPs when the molecular
target of the protein are located within the lymphatic system
or at the SC site, leading to dose-dependent bioavailability.
For example, dose-dependent bioavailability has been ob-
served for hGH and EPO (47,50). In addition, consideration
of TMDD in the model may improve the predictions for TPs
where systemic clearance changes with dose due to target
receptor saturation. One advantage of the model structure
used here is the ability to predict interstitial concentration,
which represents the driving concentration of TMDD for
membrane-bound target receptors located on the cell
surface. Use of the total tissue concentration to model
TMDD in such cases would underestimate the concentration
at the receptor site as the TPs often do not distribute into the
tissue cells themselves and hence total tissue concentration
will be lower than Ci.
The current PBPK model could be expanded to incorpo-
rate the FcRn recycling mechanism for mAbs and also TMDD
models. However, further work is required to understand pre-
systemic catabolism/degradation before these processes can be
predicted with a true bottom-up approach. In vitro incubation of
TPs with SC tissue homogenate, lymph and blood (89,90) may
help to inform such models in the future. With increased
understanding of these processes and their importance for SC
bioavailability, the current PBPK model can be expanded to
mechanistically describe bioavailability and absorption rate. In
addition, the impact of factors such as TP charge, formulation
and patient characteristics on SC absorption rate may be
incorporated. The current model is however a suitable starting
point for bottom-up prediction of the rate of SC absorption.
Another important consideration when predicting drug kinetics
is obtaining an accurate representation of the variability within a
given population (91). Although the current study focuses on
predictions for an average person, future work is intended to
explore the prediction of population variability in absorption
following SC dosing.
CONCLUSION
A mechanistic whole-body PBPK model has been
developed to predict absorption rate of TPs following SC
dosing via both direct diffusion through capillaries into blood
and through lymphatic absorption. The model provided
reasonable prediction of SC absorption using a bottom-up
approach based on TP molecular size as the model input. One
third to half the Cmax and tmax predictions fell within 0.8–1.25-
fold of the observed values. Although a general trend for
underprediction of tmax was observed, no correlation with
molecular size or pI was apparent. Further enhancement in
the future to include mechanistic prediction of distribution at
the injection site and through the interstitial space as well as
pre-systemic elimination will allow a true bottom-up ap-
proach for prediction of TP SC absorption.
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